Skip to main content
Premium Trial:

Request an Annual Quote

BioDirection Extends License Agreement With Nanosys to Include Sepsis

NEW YORK (360Dx) – BioDirection said Thursday that it has inked an exclusive worldwide license for development of its Tbit diagnostic platform to diagnose and monitor sepsis.

The agreement is an extension of a deal in place since 2012 when BioDirection licensed a portfolio of 14 patents from quantum-dot company Nanosys for development of a diagnostic platform to detect traumatic brain injury at the point of care.

Financial and other terms of the agreement were not disclosed.

BioDirection's executive chairman James Wylie said that the firm is seeking a partner to support development and accelerate commercialization of the Tbit diagnostic platform for sepsis. He said that the patents it has licensed from Nanosys were first developed by Charles Lieber's research group at Harvard University.

According to BioDirection, its portable diagnostic platform is based on proprietary nanowire technology and a biosensor that rapidly detects and measures the presence and concentration of specific biomarker molecules from bodily fluids, including inflammatory biomarkers associated with sepsis.

The platform is being designed to provide answers within minutes, which could be especially effective for conditions such as traumatic brain injury and sepsis that require fast results so that clinicians can respond as needed, Wylie said.

Brian McGlynn, founder and chief technology officer of BioDirection, said in a statement that for sepsis diagnostics, the firm's platform is being developed to provide "actionable information" whether the patient presents with symptoms in the emergency room or acquires an infection during a hospital stay.